ReviewMicrobial pathogenesis2013
New technologies in developing recombinant attenuated Salmonella vaccine vectors.
Review in Microbial pathogenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Combatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination.BMC infectious diseases · 2025Pooled it
- Self-destructing attenuated adjuvant Salmonella serves as a safe and potent live vaccine adjuvant.NPJ vaccines · 2026Article
- Current Applications and Immunological Considerations ofMicroorganisms · 2026Review
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Recombinant Live-AttenuatedVaccines · 2024Review
- Chitosan-nanoparticle-based oral Salmonella enteritidis subunit vaccine elicits cross-protection against Salmonella typhimurium in broilers.Poultry science · 2024Article
- The Trimeric Autotransporter Adhesin SadA fromVaccines · 2024Article
- Multimodal vaccination targeting the receptor binding domains ofMicrobiology spectrum · 2024Article
- Recombinant AttenuatedVaccines · 2023Article
- Recombinant-attenuated Salmonella enterica serovar Choleraesuis vector expressing the PlpE protein of Pasteurella multocida protects mice from lethal challenge.BMC veterinary research · 2023Article
- Oral Immunization with AttenuatedMicrobiology spectrum · 2022Article
- Article
- Protective immunity enhancedFrontiers in immunology · 2022Article
- Non-Antibiotics Strategies to ControlAnimals : an open access journal from MDPI · 2022Review
- Strategies for Enhancement of Live-AttenuatedVaccines · 2021Review
- Construction and Evaluation of Recombinant AttenuatedFrontiers in immunology · 2021Article
- Optimized AttenuatedFrontiers in microbiology · 2021Article
- Article
- Uncoupling of invasive bacterial mucosal immunogenicity from pathogenicity.Nature communications · 2020Article
- Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant attenuated Salmonella vaccine (RASV) vectors producing recombinant gene-encoded protective antigens should have special traits. These features ensure that the vaccines survive stresses encountered in the gastrointestinal tract following oral vaccination to colonize lymphoid tissues without causing disease symptoms and to result in induction of long-lasting protective immune responses. We recently described ways to achieve these goals by using regulated delayed in vivo attenuation and regulated delayed in vivo antigen synthesis, enabling RASVs to efficiently colonize effector lymphoid tissues and to serve as factories to synthesize protective antigens that induce higher protective immune responses. We also developed some additional new strategies to increase vaccine safety and efficiency. Modification of lipid A can reduce the inflammatory responses without compromising the vaccine efficiency. Outer membrane vesicles (OMVs) from Salmonella-containing heterologous protective antigens can be used to increase vaccine efficiency. A dual-plasmid system, possessing Asd+ and DadB+ selection markers, each specifying a different protective antigen, can be used to develop multivalent live vaccines. These new technologies have been adopted to develop a novel, low-cost RASV synthesizing multiple protective pneumococcal protein antigens that could be safe for newborns/infants and induce protective immunity to diverse Streptococcus pneumoniae serotypes after oral immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.